Character Biosciences Secures $93M for Clinical Trials Targeting Dry AMD

Character Biosciences has raised $93 million in a Series B funding round to advance clinical trials for two programs aimed at treating dry age-related macular degeneration (AMD). The biotech company plans to focus on geographic atrophy, an advanced stage of the disease. This funding will support testing of therapies designed to address different stages of the condition, which currently has limited treatment options.

The announcement follows recent FDA approvals for geographic atrophy treatments from Apellis Pharmaceuticals and Astellas Pharma. Character Biosciences claims its approach could offer a competitive alternative in this space. The company aims to develop what it describes as “best-in-class” therapies, though specific details about its drug candidates or trial timelines have not been disclosed.

Date: March, 2025

Newsflash | Powered by GeneOnline AI

Related posts:

Breakthrough Study Suggests Common Antibiotic Vancomycin Could Treat Specific Inflammatory Bowel Disease Reimagining Clinical Trials: Building Infrastructure for Made-to-Order Therapies Study Reports Improved Brain Infection Diagnosis and Care in Brazil, India, and Malawi FDA Approves New Oral Antibiotic for Urinary Tract Infections

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後